Trusted Resources: Evidence & Education
Scientific literature and patient education texts
How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease
source: British Journal of Haematology
authors: Gardner K, Hoppe C, Mijovic A, Thein SLsummary/abstract:
Transfusion therapy is effective in the prevention and treatment of many complications of sickle cell disease (SCD). However, its benefits must be balanced against its risks, including delayed haemolytic transfusion reactions (DHTR). Not only is the relative rate of alloimmunization higher in patients with SCD than in other patient populations, but attendant risks associated with DHTR are even greater in SCD. Clinicians’ awareness of DHTR events is poor because symptoms of DHTR mimic acute vaso-occlusive pain and immunohaematology findings are often negative. Transfusions delivered in the acute rather than elective setting appear to confer a higher risk of DHTR. Management of DHTR in SCD depends on the clinical severity, ranging from supportive care to immunosuppression, and optimization of erythropoiesis. DHTR must be considered in any recently transfused patient presenting with acute sickle cell pain. Meticulous documentation of transfusion and immunohaematology history is key. We anticipate an increase in DHTR events in SCD patients with the increasing use of red blood cell transfusion therapy.organization: King's College London; King's College Hospital NHS Foundation Trust, London; Children's Hospital and Research Center Oakland; National Institutes of Health/National Heart Lung and Blood Institute, Bethesda, USA
read more full text
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
ASH Clinical Practice Guidelines on Sickle Cell Disease (SCD)https://www.youtube.com/watch?v=tozUcTSN...
FDA Clears Graphite Bio to Begin Trial for Gene Therapy in Sickle Cell DiseaseIn response to Graphite Bio’s investig...
Disability evaluation under social security (hematological disorders-adult)A. What hematological disorders do we ev...
How organ and tissue transplants can affect buying life insuranceEach day in the United States, about 80 ...
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.